廣告

2018年7月7日 星期六

矽谷最大醜聞;Bad Blood: Secrets and Lies in a Silicon Valley startup. Theranos 公司衰亡記 Theranos and the Dark Side of Storytelling


'Bad Blood' Review: The Biggest Scam in Silicon Valley | GQ

https://www.gq.com/story/bad-blood-review


Bad Blood: Secrets and Lies in a Silicon Valley Startup: John ...



https://www.amazon.com/Bad-Blood-Secrets-Silicon.../152473165X
An Amazon Best Book of May 2018: In Bad Blood, the Wall Street Journal's John Carreyrou takes us through the step-by-step history of Theranos, a Silicon Valley startup that became almost mythical, in no small part due to its young, ...


2016.10   Harvard Business Review

Stories from 'Bad Blood' book on Theranos and Elizabeth Holmes
https://www.cnbc.com/.../stories-from-bad-blood-book-on-theranos...



2018/05/22 - It's been three years since The Wall Street Journal's John Carreyrou first started exposing the fraud at blood-testing startup Theranos. Now, Carreyrou has delivered his long-awaited book about the onetime Silicon Valley ...

'Bad B

Business professionals should read the story of Theranos as a cautionary tale that carries at least two big lessons.



A powerful, emotion-drenched story is at the heart of every con job.
HBR.ORG

Wikipedia
Theranos is an American privately held consumer health-technology company based in Palo Alto, California.[1] It is under criminal investigation by federal prosecutors and the Securities and Exchange Commission.[2]
Theranos developed a blood-testing device named Edison. The company said the device uses a few drops of blood obtained via a finger-stick, rather than vials of blood obtained via traditional venipuncture,[3] utilizing microfluidics technology.[4] By the summer of 2014, its founders had raised over $400 million from investors, valuing the company at $9 billion.[5][6]
In October 2015, controversy surrounding the company's blood testing process arose after a report in The Wall Street Journal raised concerns about the accuracy of its Edison device. An independent U.S. government review by the Centers for Medicare and Medicaid Services (CMS) reported inaccurate testing results and multiple deficiencies in sample handling during a recent inspection.
In June 1, 2016, Forbes revised its estimate of the company's net worth to $800 million.[7][8]
On July 7, 2016, Theranos announced that it had received notice from the Centers for Medicare & Medicaid Services (CMS) regarding the revocation of its CLIA certificate. Sanctions include a prohibition of the owners and operators from owning or operating a lab for two years and a civil monetary penalty.[9][10]
On October 5, 2016, Theranos announced that it would close its laboratory operations, shutter its wellness centers and lay off around 40 percent of its work force, while henceforth focusing on an initiative to create miniature medical testing machines.[11]

沒有留言:

網誌存檔